CollabRx, Inc. CLRX, a data analytics company focused on genomics, today announced that Chairman and CEO Thomas R. Mika is scheduled to present at Biotech Showcase™ 2013 on Wednesday, January 9, 2013, at 2:45 p.m. Pacific Standard Time. The January 9-11 conference is to be held at the Parc55 Wyndham San Francisco-Union Square in San Francisco.
Now in its fifth year, Biotech Showcase™ is an investor and partnering conference that brings together healthcare companies, investors and pharmaceutical executives. Nearly 1,400 were in attendance at last year's event.
CollabRx uses cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the world's knowledge on molecular medicine with specific insights from the nation's top clinical experts. The company combines proprietary content and technology to provide clinically relevant and dynamically updated knowledge on clinical trials, drugs, biologics and other information relevant for cancer treatment planning. This knowledge is supported by CollabRx's large and growing network of over 50 leading clinical practitioners in the United States. While CollabRx and its advisors do not provide specific treatment recommendations, this clinically relevant knowledge is a key part of the “context engine” for informing healthcare decision-making.
About Biotech Showcase™ 2013
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week, which is widely viewed as setting the tone for the coming year. For more information, please visit www.ebdgroup.com/bts.
CollabRx, Inc. CLRX is a data analytics company and a leader in cloud-based expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
Thomas R. Mika, Chairman and CEO, 415-248-5350
Robert Ferri Partners, LLC
Robert Ferri, 415-575-1589 (direct)
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.